O	0	11	Recombinant	Recombinant	JJ	B-NP
O	12	17	human	human	JJ	I-NP
O	18	29	prothrombin	prothrombin	NN	I-NP
O	30	37	kringle	kringle	NN	I-NP
O	37	38	-	-	HYPH	O
O	38	39	2	2	CD	B-NP
O	40	48	inhibits	inhibit	VBZ	B-VP
B-Cancer	49	55	B16F10	B16F10	NN	B-NP
I-Cancer	56	64	melanoma	melanoma	NN	I-NP
O	65	75	metastasis	metastasis	NN	I-NP
O	76	83	through	through	IN	B-PP
O	84	94	inhibition	inhibition	NN	B-NP
O	95	97	of	of	IN	B-PP
O	98	116	neovascularization	neovascularization	NN	B-NP
O	117	120	and	and	CC	I-NP
O	121	130	reduction	reduction	NN	I-NP
O	131	133	of	of	IN	B-PP
O	134	140	matrix	matrix	NN	B-NP
O	141	158	metalloproteinase	metalloproteinase	NN	I-NP
O	159	169	expression	expression	NN	I-NP
O	169	170	.	.	.	O

O	171	183	Angiogenesis	Angiogenesis	NN	B-NP
O	183	184	,	,	,	O
O	185	186	a	a	DT	B-NP
O	187	192	multi	multi	AFX	I-NP
O	192	193	-	-	HYPH	I-NP
O	193	197	step	step	NN	I-NP
O	198	205	process	process	NN	I-NP
O	206	211	which	which	WDT	B-NP
O	212	220	involves	involve	VBZ	B-VP
B-Cell	221	232	endothelial	endothelial	JJ	B-NP
I-Cell	233	237	cell	cell	NN	I-NP
O	238	251	proliferation	proliferation	NN	I-NP
O	251	252	,	,	,	O
O	253	261	adhesion	adhesion	NN	B-NP
O	261	262	,	,	,	O
O	263	272	migration	migration	NN	B-NP
O	272	273	,	,	,	O
O	274	277	and	and	CC	O
B-Cellular_component	278	286	basement	basement	NN	B-NP
I-Cellular_component	287	295	membrane	membrane	NN	I-NP
O	296	297	(	(	(	O
B-Cellular_component	297	299	BM	BM	NN	B-NP
O	299	300	)	)	)	O
O	301	312	degradation	degradation	NN	B-NP
O	312	313	,	,	,	O
O	314	316	is	be	VBZ	B-VP
O	317	326	essential	essential	JJ	B-ADJP
O	327	330	for	for	IN	B-PP
B-Cancer	331	336	tumor	tumor	NN	B-NP
O	337	347	metastasis	metastasis	NN	I-NP
O	347	348	.	.	.	O

O	349	353	Here	Here	RB	B-ADVP
O	354	356	we	we	PRP	B-NP
O	357	361	show	show	VBP	B-VP
O	362	366	that	that	IN	B-SBAR
O	367	378	recombinant	recombinant	JJ	B-NP
O	379	384	human	human	JJ	I-NP
O	385	396	prothrombin	prothrombin	NN	I-NP
O	397	404	kringle	kringle	NN	I-NP
O	404	405	-	-	HYPH	B-NP
O	405	406	2	2	CD	I-NP
O	407	408	(	(	(	O
O	408	410	rk	rk	NN	B-NP
O	410	411	-	-	HYPH	O
O	411	412	2	2	CD	B-NP
O	412	413	)	)	)	O
O	414	423	inhibited	inhibit	VBD	B-VP
O	424	430	bovine	bovine	JJ	B-NP
B-Cell	431	440	capillary	capillary	JJ	I-NP
I-Cell	441	452	endothelial	endothelial	JJ	I-NP
I-Cell	453	457	cell	cell	NN	I-NP
O	458	467	migration	migration	NN	I-NP
O	468	472	with	with	IN	B-PP
O	473	475	an	an	DT	B-NP
O	476	478	IC	IC	NN	I-NP
O	478	479	(	(	(	O
O	479	481	50	50	CD	B-NP
O	481	482	)	)	)	O
O	483	484	(	(	(	O
O	484	497	concentration	concentration	NN	B-NP
O	498	501	for	for	IN	B-PP
O	502	506	half	half	DT	B-NP
O	507	514	maximal	maximal	JJ	I-NP
O	515	525	inhibition	inhibition	NN	I-NP
O	525	526	)	)	)	O
O	527	529	of	of	IN	B-PP
O	530	532	38	38	CD	B-NP
O	533	535	nM	nM	NN	I-NP
O	536	539	and	and	CC	O
O	540	549	inhibited	inhibit	VBD	B-VP
O	550	558	adhesion	adhesion	NN	B-NP
O	559	561	to	to	TO	B-PP
B-Cellular_component	562	575	extracellular	extracellular	JJ	B-NP
I-Cellular_component	576	582	matrix	matrix	NN	I-NP
O	583	584	(	(	(	O
B-Cellular_component	584	587	ECM	ECM	NN	B-NP
O	587	588	)	)	)	O
O	589	597	proteins	protein	NNS	B-NP
O	597	598	.	.	.	O

O	599	606	Because	Because	IN	B-SBAR
B-Cancer	607	612	tumor	tumor	NN	B-NP
O	613	623	metastasis	metastasis	NN	I-NP
O	624	632	requires	require	VBZ	B-VP
O	633	645	angiogenesis	angiogenesis	NN	B-NP
O	645	646	,	,	,	O
O	647	649	we	we	PRP	B-NP
O	650	658	examined	examine	VBD	B-VP
O	659	666	whether	whether	IN	B-SBAR
O	667	669	rk	rk	NN	B-NP
O	669	670	-	-	HYPH	O
O	670	671	2	2	CD	B-NP
O	672	677	could	could	MD	B-VP
O	678	685	inhibit	inhibit	VB	I-VP
B-Cancer	686	696	metastases	metastasis	NNS	B-NP
O	697	704	induced	induce	VBN	B-VP
O	705	707	by	by	IN	B-PP
O	708	717	injection	injection	NN	B-NP
O	718	720	of	of	IN	B-PP
B-Cell	721	727	B16F10	B16F10	NN	B-NP
I-Cell	728	736	melanoma	melanoma	NN	I-NP
I-Cell	737	742	cells	cell	NNS	I-NP
O	743	747	into	into	IN	B-PP
O	748	752	mice	mouse	NNS	B-NP
O	752	753	.	.	.	O

O	754	757	The	The	DT	B-NP
O	758	765	results	result	NNS	I-NP
O	766	774	revealed	reveal	VBD	B-VP
O	775	779	that	that	IN	B-SBAR
O	780	783	the	the	DT	B-NP
B-Cancer	784	794	metastatic	metastatic	JJ	I-NP
I-Cancer	795	801	tumors	tumor	NNS	I-NP
O	802	804	in	in	IN	B-PP
O	805	810	mouse	mouse	NN	B-NP
B-Organ	811	815	lung	lung	NN	I-NP
O	816	820	were	be	VBD	B-VP
O	821	829	markedly	markedly	RB	I-VP
O	830	839	decreased	decrease	VBN	I-VP
O	840	842	in	in	IN	B-PP
O	843	844	a	a	DT	B-NP
O	845	849	dose	dose	NN	I-NP
O	849	850	-	-	HYPH	B-NP
O	850	859	dependent	dependent	JJ	I-NP
O	860	866	manner	manner	NN	I-NP
O	867	870	and	and	CC	O
O	871	876	acute	acute	JJ	B-NP
B-Organ	877	881	lung	lung	NN	I-NP
O	882	888	injury	injury	NN	I-NP
O	889	896	induced	induce	VBN	B-VP
O	897	899	by	by	IN	B-PP
B-Cancer	900	906	B16F10	B16F10	NN	B-NP
I-Cancer	907	915	melanoma	melanoma	NN	I-NP
O	916	926	metastasis	metastasis	NN	I-NP
O	927	930	was	be	VBD	B-VP
O	931	941	diminished	diminish	VBN	I-VP
O	942	944	by	by	IN	B-PP
O	945	953	systemic	systemic	JJ	B-NP
O	954	956	rk	rk	NN	I-NP
O	956	957	-	-	HYPH	O
O	957	958	2	2	CD	B-NP
O	959	968	treatment	treatment	NN	I-NP
O	968	969	.	.	.	O

O	970	972	In	In	IN	B-PP
O	973	992	immunohistochemical	immunohistochemical	JJ	B-NP
O	993	1001	analysis	analysis	NN	I-NP
O	1001	1002	,	,	,	O
O	1003	1005	rk	rk	NN	B-NP
O	1005	1006	-	-	HYPH	B-NP
O	1006	1007	2	2	CD	I-NP
O	1008	1015	reduced	reduce	VBN	I-NP
O	1016	1026	expression	expression	NN	I-NP
O	1027	1029	of	of	IN	B-PP
O	1030	1038	vascular	vascular	JJ	B-NP
O	1039	1050	endothelial	endothelial	JJ	I-NP
O	1051	1057	growth	growth	NN	I-NP
O	1058	1064	factor	factor	NN	I-NP
O	1064	1065	,	,	,	O
O	1066	1071	which	which	WDT	B-NP
O	1072	1074	is	be	VBZ	B-VP
O	1075	1076	a	a	DT	B-NP
O	1077	1083	potent	potent	JJ	I-NP
O	1084	1094	angiogenic	angiogenic	JJ	I-NP
O	1095	1104	activator	activator	NN	I-NP
O	1105	1108	and	and	CC	I-NP
O	1109	1127	neovascularization	neovascularization	NN	I-NP
O	1128	1130	in	in	IN	B-PP
O	1131	1134	the	the	DT	B-NP
O	1135	1140	mouse	mouse	NN	I-NP
B-Organ	1141	1145	lung	lung	NN	I-NP
O	1145	1146	.	.	.	O

O	1147	1151	Also	Also	RB	B-ADVP
O	1151	1152	,	,	,	O
O	1153	1155	rk	rk	NN	B-NP
O	1155	1156	-	-	HYPH	O
O	1156	1157	2	2	CD	B-NP
O	1158	1168	diminished	diminish	VBD	B-VP
O	1169	1172	the	the	DT	B-NP
O	1173	1183	expression	expression	NN	I-NP
O	1184	1186	of	of	IN	B-PP
O	1187	1193	matrix	matrix	NN	B-NP
O	1194	1211	metalloproteinase	metalloproteinase	NN	I-NP
O	1211	1212	-	-	HYPH	B-NP
O	1212	1213	2	2	CD	I-NP
O	1214	1217	and	and	CC	O
O	1218	1219	-	-	HYPH	B-NP
O	1219	1220	9	9	CD	I-NP
O	1221	1223	in	in	IN	B-PP
O	1224	1227	the	the	DT	B-NP
O	1228	1233	mouse	mouse	NN	I-NP
B-Organ	1234	1238	lung	lung	NN	I-NP
O	1239	1244	which	which	WDT	B-NP
O	1245	1252	induces	induce	VBZ	B-VP
B-Cancer	1253	1258	tumor	tumor	NN	B-NP
O	1259	1269	metastasis	metastasis	NN	I-NP
O	1270	1273	and	and	CC	I-NP
O	1274	1286	angiogenesis	angiogenesis	NN	I-NP
O	1286	1287	.	.	.	O

O	1288	1293	These	These	DT	B-NP
O	1294	1298	data	datum	NNS	I-NP
O	1299	1306	suggest	suggest	VBP	B-VP
O	1307	1311	that	that	IN	B-SBAR
O	1312	1322	inhibition	inhibition	NN	B-NP
O	1323	1325	of	of	IN	B-PP
B-Cancer	1326	1332	B16F10	B16F10	NN	B-NP
I-Cancer	1333	1341	melanoma	melanoma	NN	I-NP
O	1342	1352	metastasis	metastasis	NN	I-NP
O	1353	1355	by	by	IN	B-PP
O	1356	1358	rk	rk	NN	B-NP
O	1358	1359	-	-	HYPH	O
O	1359	1360	2	2	CD	B-NP
O	1361	1364	was	be	VBD	B-VP
O	1365	1371	caused	cause	VBN	I-VP
O	1372	1374	by	by	IN	B-PP
O	1375	1385	inhibition	inhibition	NN	B-NP
O	1386	1388	of	of	IN	B-PP
O	1389	1407	neovascularization	neovascularization	NN	B-NP
O	1408	1411	and	and	CC	I-NP
O	1412	1421	reduction	reduction	NN	I-NP
O	1422	1424	of	of	IN	B-PP
O	1425	1431	matrix	matrix	NN	B-NP
O	1432	1449	metalloproteinase	metalloproteinase	NN	I-NP
O	1450	1460	expression	expression	NN	I-NP
O	1460	1461	.	.	.	O

